Corporate	  Presenta,on	           October	  2011	  
MISSION	             Edge	  was	  founded	  under	  the	  belief	  that	  	    site-­‐specific,	  sustained-­‐release	  del...
DELAYED	  CEREBRAL	  ISCHEMIA	  (DCI)	               Primary	  injury,	  oEen	  caused	  by	  aneurysm	  or	  head	  	    ...
SUBARACHNOID	  HEMORRHAGE	  (SAH)	  SAH	  is	  a	  silent	  epidemic	  that	  results	  in	  staggering	  direct	  and	  i...
CURRENT	  STANDARD	  OF	  CARE	                               ACTIVE	  AGENT,	  POOR	  DELIVERY	  Oral	  nimodipine	  (Ac,...
EDGE	  TECHNOLOGY	                                AN	  ELEGANT	  DELIVERY	  SOLUTION	     Site-­‐specific,	  sustained	  re...
CONTINUOUS	  MICROENCAPSULATION	                PROCESS	  THRU	  FINISHED	  PRODUCT	  7	  |	  
THE	  “NIMO”	  FRANCHISE	    Agent                      Indication                              Pre-Clinical Development  ...
NIMOGEL 	  F         TM                                                        OR    	  SURGICAL	  CLIPPING	  •  Biodegrad...
TM	                                   NIMOVENT 	  F                        OR 	  ENDOVASCULAR	  COILING	  •  Biodegradable...
DELIVERY	  SYSTEM	  PROOF	  OF	  CONCEPT	  Site-­‐specific,	  Sustained-­‐release	  –	  Human	  Data	  	  Therapeu*c	  Dose...
NIMOGEL	  &	  NIMOVENT	  DELIVERY	  PROFILE	  •             Nimodipine	  micropar<cles	  (NimoGel	  &	  NimoVent)	        ...
EMERGING	  TREATMENT	  PARADIGM	                NIMODIPINE:	  A	  MULTIPLE	  PATHWAY	  APPROACH	                          ...
PROOF	  OF	  PRINCIPLE:	  	  STUDY	  DESIGN	          •             Dog	  double	  hemorrhage	  model	  of	  SAH	         ...
PROOF	  OF	  PRINCIPLE	  STUDY	                                                              THERAPEUTICS	  LEVELS	  TO	  ...
PHASE	  2	  STUDY	                 FDA	  confirmed	  505(b)(2)	  path	  for	  NimoGel:	  	  Relevance	  is	  NimoGel	  can...
PHASE	  2	  STUDY	  DESIGN	  Phase	  2a:	  Dose	  Finding	  Study	  [Con<nuous	  Reassessment	  Model	  (CRM)]	           ...
PHASE	  3	  STUDY	  DESIGN	    FDA	  &	  Edge	  are	  aligned	  on	  Phase	  3	  endpoints	    Phase	  3:	  Efficacy	  and	 ...
DCI	  MARKET	  OPPORTUNITY	                                               SPECIFIC	  AND	  ADDRESSABLE	  DCI	  is	  a	  gr...
BROADER	  MARKET	  OPPORTUNITIES	                                                                                         ...
DoD	  APPLICATION	  •  A	  study	  evaluated	  all	  in-­‐pa<ents	  with	  blast-­‐	     related	  neurotrauma	  from	  Op...
WELL	  PROTECTED	  FRANCHISE	                Layered	  Intellectual	  Property	  	                                       C...
KEY	  PERSONNEL	                      Management	                                             Board	  &	  Key	  Advisors	 ...
MILESTONES	  Corporate	  development	  and	  capitaliza,on	  to	  date	  –  Raised	  almost	  $4M	  in	  financing	  from	 ...
SUMMARY	  •  Well-­‐defined,	  addressable	  unmet	  worldwide	  medical	  need	  •  De-­‐risked	  lead	  assets	  with	  p...
LIMITED	  INVESTMENT	  /	  LARGE	  UPSIDE	  	                        Development	  Timeline:	  2.5	  to	  3	  years	      ...
Corporate	  Presenta,on	           October	  2011	  
Upcoming SlideShare
Loading in …5
×

Edge Corporate Presentation 10.21.11

772 views

Published on

Edge Corporate Presentation
October 2011

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
772
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
9
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Edge Corporate Presentation 10.21.11

  1. 1.  Corporate  Presenta,on   October  2011  
  2. 2. MISSION   Edge  was  founded  under  the  belief  that     site-­‐specific,  sustained-­‐release  delivery  of  medicines   directly  to  the  site  of  brain  injury  will  prevent  certain  delayed  and  life-­‐threatening  condi<ons,  improve  pa<ent   outcomes,  and  decrease  overall  cost  of  care  
  3. 3. DELAYED  CEREBRAL  ISCHEMIA  (DCI)   Primary  injury,  oEen  caused  by  aneurysm  or  head     trauma,  is  rou<nely  addressed   PRIMARY  EVENT   DAY  1   DAY  3-­‐14     ISCHEMIA  /  NEURONAL   BRAIN  ARTERIES   VASOCONSTRICTION   DEATH   Secondary  injury  (DCI)  is  caused  by  a  complex   biochemical  cascade  leading  to  vasoconstric*on,   ischemia  and,  ul<mately,  neuronal  death  3  |   Source:  American  Heart  Associa<on    
  4. 4. SUBARACHNOID  HEMORRHAGE  (SAH)  SAH  is  a  silent  epidemic  that  results  in  staggering  direct  and  indirect  costs  to  society.    •  Average  age  50  years  old  •  90%  of  pa<ents  arrive  alive  to  the  hospital  •  Poor  30-­‐day  prognosis  •  Costs  exceed  $25B  annually  for  aneurysmal  SAH     Of patients arriving alive to the hospital… 2 die 2 permanent brain damage 1 resumes normal activity4  |   4
  5. 5. CURRENT  STANDARD  OF  CARE   ACTIVE  AGENT,  POOR  DELIVERY  Oral  nimodipine  (Ac,ve  Systemic  Agent)   •  Generic  calcium  channel  blocker  (FDA  approved  in  1989)  rou<nely  given   to  all  pa<ents     •  Rinkel  et.  al.  (8  trials  reviewed)  showed  improved  outcome  and  reduced   cerebral  infarc<on  with  minimal  effect  on  angiographic  vasospasm   •  Standard  oral  dose  of  nimodipine  is  60  mg  every  4  hours  x  21  days    However…  Dose  is  sub-­‐op,mal  (Poor  Delivery)   •  Cerebrospinal  fluid  (CSF)  concentra<on  is  0.4  ng/ml   –  CSF  concentra<on  is  at  least  10x  too  low  to  dilate  arteries   •  Maximal  plasma  concentra<on  of  about  20  ng/ml   –  Dose-­‐limi<ng  hypotension  in  >30%  of  pa<ents   •  Hypotension  occurs  at  plasma  concentra<on  >30-­‐40  ng/ml   –  Oral  nimodipine  gets  above  this,  yet  CSF  concentra<ons  too  low    5  |  
  6. 6. EDGE  TECHNOLOGY   AN  ELEGANT  DELIVERY  SOLUTION   Site-­‐specific,  sustained  release  bioabsorbable  poly(D,L-­‐lac*de-­‐co-­‐glycolide)  (PLGA)-­‐ based  micropar*cles   •  Handling  characteris<cs   –  Minimizes  systemic  side  effects   –  Circumvents  blood-­‐brain  barrier   –  One-­‐<me  administra<on   •  Administered  during/aEer  surgery   –  Does  not  require  addi<onal  surgery  or  procedures  to  apply   –  Simple  prep/administra<on  does  not  interfere  with  surgery  workflow   –  NOT  an  emergency  care  administra<on   •  Proven  commercially  feasible  technology  (scaled-­‐up  for  commercial   produc<on)   •  Backed  by  strong  IP  poriolio  6  |  
  7. 7. CONTINUOUS  MICROENCAPSULATION   PROCESS  THRU  FINISHED  PRODUCT  7  |  
  8. 8. THE  “NIMO”  FRANCHISE   Agent Indication Pre-Clinical Development Phase 2 Formulation In Vitro In Vivo Clinical Development Reduce DCI and improve 30-day outcome in patients with aSAH NimoGel* undergoing neurosurgical clipping (intracisternal) (EG-1961) Moderate to severe head trauma Reduce DCI and improve 30-day outcome in patients with aSAH undergoing endovascular coiling. NimoVent* (intraventricular) (EG-1962) Moderate to severe head trauma EG-1964 Chronic subdural hematoma Post-craniotomy Spontaneous intracerebral EG-1960* hemorrhage Moderate to severe head trauma*Denotes: Department of Defense Interest Potential
  9. 9. NIMOGEL  F TM OR  SURGICAL  CLIPPING  •  Biodegradable  polymer  encapsula<on  of   nimodipine  (FDA  505  (b)(2)  approval)  and   hyaluronic  acid  (HA)  carrier  •  14  days  release  •  Applied  directly  to  the  injury  site   (intracisternally)  during     surgical  clipping  to  secure  the  bleeding     aneurysm    •  Designed  to  provide  consistent  and   therapeu<c  concentra<ons  of  nimodipine  to   prevent  DCI  while  minimizing  side  effects  APPLICATION:  To  reduce  delayed  cerebral  ischemia  and  improve  30-­‐day  outcome  in  pa8ents  with  aneurysmal  SAH  undergoing   SURGICAL  neurosurgical  clipping.   CLIPPING  9  |  
  10. 10. TM   NIMOVENT  F OR  ENDOVASCULAR  COILING  •  Biodegradable  polymer  encapsula<on  of   nimodipine  (505  (b)(2)  approval)  and  buffer    •  14  days  release  •  Designed  to  reduce  ischemia  deficits  and   improve  outcomes  in  pa<ents  who  undergo   endovascular  coiling  •  NimoVent  delivery  is  minimally  invasive   –  No  addi<onal  procedure  required   ENDOVASCULAR   –  Delivered  in  the  intensive  care  unit  aEer  the   COILING   pa<ent  has  undergone  endovascular  coiling   through  an  exis<ng  intraventricular  catheter   inserted  to  measure  intracranial  pressure  (ICP)      APPLICATION:  To  reduce  delayed  cerebral  ischemia  and  improve  30-­‐day  outcome    in  pa8ents  with  aneurysmal  SAH  undergoing  endovascular  coiling.  10  |  
  11. 11. DELIVERY  SYSTEM  PROOF  OF  CONCEPT  Site-­‐specific,  Sustained-­‐release  –  Human  Data    Therapeu*c  Doses  Of  Calcium  Channel  Blockers  Improve  Outcome  •  Studied  in  252*  pa,ents  in  Japan  and  Germany  (Krischek  2007,  Barth   2007,  Kasuya  2002,  2005,  2011)   –  Angiographic  vasospasm  decreased  from  73%  control  to  7%  nicardipine   –  Mortality  decreased  from  38%  to  6%   –  No  side  effects  •  Pellets  not  commercializable,  difficult  to  administer,  cannot  be  injected   into  ventricles  (endovascular  coiling  /  closed  head  injury)   *  Subarachnoid  nicardipine  in  poly(D,L-­‐lac<de  co  glycolide)  (PLGA)  pellets  11  |  
  12. 12. NIMOGEL  &  NIMOVENT  DELIVERY  PROFILE  •  Nimodipine  micropar<cles  (NimoGel  &  NimoVent)   •  Nimodipine  in  PLGA  micropar<cles   •  Toothpaste-­‐like  gel  to  retain  NimoGel  in  subarachnoid  space,  liquid   NimoVent  allows  diffusion  from  ventricles  to  subarachnoid  space   •  Easy  to  administer  for  both  clipped  and  coiled  pa<ents   •  Ability  to  scale-­‐up,  easily  sterilized  via  gamma  irradia<on,  stable  12  |  
  13. 13. EMERGING  TREATMENT  PARADIGM   NIMODIPINE:  A  MULTIPLE  PATHWAY  APPROACH   Subarachnoid Hemorrhage Transient Global Subarachnoid Ischemia Blood Cortical Oxidative Stress / Angiographic Microthrombo- Spreading Inflammation / Vasospasm embolism Ischemia Other? Focal Cerebral Global Cerebral Infarctions Atrophy Delayed Cerebral Ischemia (DCI) Poor Outcome13  |  
  14. 14. PROOF  OF  PRINCIPLE:    STUDY  DESIGN   •  Dog  double  hemorrhage  model  of  SAH   •  2  doses  of  NimoVent:  30mg  and  10mg  or  placebo  (vehicle)  formula<on   •  Blood  was  injected  into  the  cisterna  magna  (Day  0  and  Day  2)   •  Dogs  underwent  angiography  on  days  0,  7  and  14   •  Endpoints:  angiographic  vasospasm,  behavior,  serum  and  CSF  nimodipine   concentra<ons,  pathology  Day  0   Day  7   14  |  
  15. 15. PROOF  OF  PRINCIPLE  STUDY   THERAPEUTICS  LEVELS  TO  THE  BRAIN;  LOW  SYSTEMIC  LEVELS   Efficacy  Results:   Safety  Results:   •  30  mg  NimoVent  prevented  vasospasm  at   •  Serum  concentra<ons  were  higher  in  30  mg   day  7  and  at  day  14   dose  compared  to  10  mg  dose   –  CSF  concentra*ons  were  more  than   •  Serum  (30  mg  and  10  mg  dose)  showed  highest   200  ng/ml   concentra<ons  on  day  2  (8  ng/ml  and  4  ng/ml)   •  No  local  inflamma<on  or  other  signs  of   –  Hypotension  occurs  at  plasma   neurotoxicity  were  observed   concentra*on  >  30-­‐40  ng/ml     Average  of  4  blinded  reviewers  %  change  from  baseline  (diameter  of  cerebral  basilar  artery)  
  16. 16. PHASE  2  STUDY    FDA  confirmed  505(b)(2)  path  for  NimoGel:    Relevance  is  NimoGel  can   refer  to  prior  toxicity  studies  for  nimodipine,  PLGA  and  HA    Edge  has  clear  path  for  IND  and  scale-­‐up  needs  and  <melines    FDA  clarified  expecta<ons  &  Edge  is  aligned  with  pre-­‐clinical  studies  for   IND  -­‐  no  change  in  the  general  plan  and  approach  proposed  by  Edge    FDA  &  Edge  are  aligned  on  Phase  2  clinical  trial  design   –  NimoGel  alone  can  be  compare  to  oral  nimodipine  (standard  of  care)   –  First  <me  in  22  years  that  FDA  has  allowed  experimental  drug  vs.  oral  nimodipine  16  |  
  17. 17. PHASE  2  STUDY  DESIGN  Phase  2a:  Dose  Finding  Study  [Con<nuous  Reassessment  Model  (CRM)]   •   n=  up  to  63  pa<ents   •  40mg,  120mg,  160mg,  up  to  1120mg  or  toxicity   •  Endpoint  plasma  levels  >40ng/mL  causing  hypotension   •  10  centers  (2  pa<ents  /  month  per  center)   •  9  months  to  complete  (3  months  start-­‐up,  4  months  to  enroll,  3  months  to  analyze  data)  Phase  2b:  Toxicity  Study   •  n=  88  pa<ents   •  NimoGel  vs.  standard  of  care  (oral  nimodipine)   •  Primary  endpoint:  toxicity   •  Exploratory  endpoints:  infarc<on  or  neurological  deteriora<on  due  to  vasospasm,  need   for  rescue  therapy,  mortality,  ICU  LOS,  Hospital  LOS       30-­‐day  endpoint,  90  day  follow-­‐up   •  15  centers  (2  pa<ents  /  month  per  center)   •  9  months  to  complete  (3  months  start-­‐up,  3  months  to  enroll,  3  months  to  analyze  data)  17  |  
  18. 18. PHASE  3  STUDY  DESIGN   FDA  &  Edge  are  aligned  on  Phase  3  endpoints   Phase  3:  Efficacy  and  Safety   •  n=  750  pa*ents   •  NimoGel  vs.  standard  of  care  (oral  nimodipine)   •  Primary  endpoint:  (composite  endpoint)  infarc<on  or  neurological   deteriora<on  due  to  vasospasm,  need  for  rescue  therapy,  mortality   •  Secondary  endpoint:  posi<ve  trend  modified  Rankin  score    30-­‐day  endpoint,  90  day  follow-­‐up   •  Health  economic  secondary  endpoints:  ICU  LOS,  Hospital  LOS   •  100  centers  worldwide  (1.5  pa<ents  /  month  per  center)   •  15  months  to  complete  (3  months  start-­‐up,  9  months  to  enroll,  3   months  to  analyze  data)  18  |  
  19. 19. DCI  MARKET  OPPORTUNITY   SPECIFIC  AND  ADDRESSABLE  DCI  is  a  great  burden  •  All  SAH  pa<ents  are  at  risk  of  DCI  •  >750,000  people/year  worldwide  are  at  risk  for  DCI  aEer  aneurysmal  SAH     Aneurysmal  SAH  is  common  in  U.S.,  E.U.,  and  Japan  •  Head  trauma  also  causes  SAH  and  are  at  risk  •  Concentrated  customer  base;  easily  covered  by  25  –  50  person  specialty  salesforce   At  Risk  Addressable  Market   Concentrated  Customers   # of U.S. % Share of Japan Percentile Hospitals patients 70,000 U.S. 100,000 1% 50 16% E.U. 5% 250 66% 100,000 10% 500 85% DCI  risk  auributed  to  all  SAH  (aneurysmal   SAH  &  head  trauma)  
  20. 20. BROADER  MARKET  OPPORTUNITIES   30-Day 30-Day MortalityAcute Neurological Incidence Incidence Average Mortality Rate orCondition U.S. World Age Rate Brain DamageRuptured BrainAneurysm – NimoGel & >40,000 >750,000 50 50% 75%NimoVentChronic Subdural >70,000 >1.5 Million 65 20% 40%Hematoma – EG-1964Intracerebral 100,000 >2 Million 60 45% 80%Hemorrhage – EG-1960 Variable on Variable on Variable onCraniotomy – EG-1960 >180,000 >2 Million condition condition conditionModerate & Severe HeadTrauma – NimoGel, >250,000 >3 Million 40 20% 50%NimoVent, EG-1960*  Source:  Leng,  L.,  Fink,  M.,  Iadecola,  C.  2010.  Spreading  Depolariza8on:  A  Possible  New  Culprit  in  the  Delayed  Cerebral  Ischemia  of  Subarachnoid  Hemorrhage.  Neurological  Review     20  |  
  21. 21. DoD  APPLICATION  •  A  study  evaluated  all  in-­‐pa<ents  with  blast-­‐   related  neurotrauma  from  Opera<on  Iraqi     Freedom  and  found  that  47%  had  blast-­‐related     vasospasm  •  In  addi<on  to  the  vasospasm  caused  by     neurotrauma,  “blast  vasospasm”  is  a  recent     phenomenon  recently  documented  in  the     medical  literature  •  DoD  has  maintained  an  ac<ve  research  program  in  reducing  injury  caused   by  hemorrhage  •  DoD  has  recognized  the  poten<al  use  of  all  of  Edge’s  products:   –  Combat  Casualty  Care  Unit  has  invited  Edge  to  submit  a  full-­‐proposal  for  NimoVent  ($4.0MM)     –  Awai<ng  an  invita<on  for  a  NimoGel  full-­‐proposal  ($4.5MM)   –  Submiued  pre-­‐proposal  to  DoD-­‐Telemedicine  &  Advanced  Technology  Research  Center  (TATRC)     –  Awai<ng  an  invita<on  from  Veteran’s  Administra<on  (VA)  for  EG-­‐1964  21  |  
  22. 22. WELL  PROTECTED  FRANCHISE   Layered  Intellectual  Property     Commercial  Barriers   “Nimo”  Franchise   •  Orphan  drug   Polymorphs  =  Composi<on   •  SurModics   of  Mauer     License,  exclusive  &   Devmt.  of  “Nimo”   worldwide   Franchise  =  Composi<on  &   Process  Patents     Produc<on  is  difficult   •  Mfg.  polymers  &   SurModics  Process  Patent   micropar<cles   NIMO   Method  of  Use  –     •  Investment  scale-­‐up   NimoGel  /  NimoVent   and  cGMP   •  FormEZE  process   •  Trade  secrets  22  |  
  23. 23. KEY  PERSONNEL   Management   Board  &  Key  Advisors   Key  Scien,fic  Advisors  Brian  A.  Leuthner,  President  &  CEO,  Co-­‐founder   Sol  Barer,  PhD,  Board  Director   Neal  F.  Kassell,  MD,  University  of  Virginia  20+  years;  Pharma  &  Specialty  Pharma,   Founder,  Former  CEO  &  Execu<ve   Health  Sciences  Center  GlaxoWellcome,  Ortho  Biotech,  ESP  Pharma,  The   Chairman,  and  Chairman,  Celgene  Medicines  Company,  Fontus  Pharmaceu<cals   Corpora<on     Daniel  Hanggi,  MD,  Heinrich-­‐Heine-­‐ University,  Dusseldorf,  Germany  R.  Loch  Macdonald,  MD,  PhD,  CSO,  Co-­‐founder   Kurt  Con,,  Board  Director  Keenan  Endowed  Chair  of  Neurosurgery,  St.   Chairman,  The  Con<  Group,  Serial   Hidetoshi  Kasuya,  MD,  Tokyo  Women’s  Michael’s  Hospital,  Toronto,  Canada;  20-­‐years  Of   entrepreneur   Medical  University,  Tokyo  Research  Led  Us  To  NimoGel  &  NimoVent;  >400   James  Louglin,  Board  Director   Peter  D.  LeRoux,  MD,  FACS,  Hospital  of  the  Peer-­‐reviewed  Ar<cles  On  Secondary  Brain  Injury   Former  Chairman,  Pension  and   University  of  Pennsylvania  Priya  Jambhekar,  MS,  Execu,ve  Vice  President,   Investment  Commiuee  of  the  KPMG  Regulatory  and  Quality   Board,  Celgene  Director,  Heads  Audit   Stephan  A.  Mayer,  MD,  Columbia   Commiuee  20+  years;  Pharma  &  Specialty  Pharma  in  product   University  Medical  Center    development,  product  safety,  quality  assurance,   Geert  Cauwenburgh,  PhD,  Advisor  quality  compliance  and  U.S.  and  interna<onal   J.  Javier  Provencio,  MD,  Cleveland  Clinic   Former  CEO,  Barrier  Therapeu<cs,  regulatory  affairs;  BMS,  J&J,  Baxter,  and  Alkemes   Hospitals   Former  VP,  R&D  Johnson  &  Johnson    Bert  Marchio,  MBA  –  CFO   Arthur  Klausner,  Advisor   Peter  Vajkoczy,  MD,  Charite  17+  years;  Specialty  Pharma  in  senior  financial   Life  sciences  venture  capitalist;  Domain   Hospital,  Berlin,  Germany  leadership  posi<ons  in  both  the  public  and  private   Associates  and  Pappas  Ventures  sectors;  Informed  Medical  Communica<ons,   Paul  M.  Vespa,  MD,  David  Geffen  School  of  MedPointe,  and  Alpharma     Medicine  at  UCLA  Carl  J.  Soranno,  Esq.,  Execu,ve  VP,  Corporate   Bryce  Weir  OC,  MSc,  FRCSC,  FACS,  FRCS  Development,  Co-­‐founder   (Ed)  hon.,  Goldblau  Professor,  The  18+  years;  prac<ce  of  law;  11  years;  Financial   University  of  Chicago  Pritzker  School  of  career  on  Wall  Street   Medicine  
  24. 24. MILESTONES  Corporate  development  and  capitaliza,on  to  date  –  Raised  almost  $4M  in  financing  from  a  small  group  of  private  investors   and  non-­‐dilu<ve  sources  –  Alliance  with  SurModics  (NASDAQ:  SRDX)  –  Proof  of  concept  in  a  dog  model  –  Successful  pre-­‐IND  mee<ng  (clear  endpoints)  –  Manufactured  large-­‐scale  batch  of  NimoGel  and  NimoVent  Timeline  &  ac,vi,es  moving  forward  –  cGMP  NimoGel  &  NimoVent  (4Q  2011)  –  Clinical  trial  –  Inves<gator  ini<ated  trial  (FPI  1Q  2012)  –  U.S.  IND  (1H  2012)  –  Orphan  drug  designa<on  (1H  2012)  –  Phase  2  Study  –  2012    –  Phase  3  Study  –  2013/2015    24  |  
  25. 25. SUMMARY  •  Well-­‐defined,  addressable  unmet  worldwide  medical  need  •  De-­‐risked  lead  assets  with  proof-­‐of-­‐concept  successfully  established  •  Clear  and  abbreviated  clinical  and  regulatory  path   –  FDA  confirmed  505(b)(2)  path  for  NimoGel   –  Orphan  drug  designa<on  eligibility   –  90  day  trial  follow  up,  short  clinical  trial  dura<on  (Phase  2  for  NimoGel   and  NimoVent)  •  High  legal,  regulatory,  R&D,  and  commercial  barriers  to   compe<<on  •  Highly  concentrated  market  and  clear  pathway  to  2015/2016   launch  •  Opportunity  for  new  indica<ons  and  addi<onal  first-­‐in-­‐class   products  25  |  
  26. 26. LIMITED  INVESTMENT  /  LARGE  UPSIDE     Development  Timeline:  2.5  to  3  years   NimoGel   NimoVent   NimoVent   EG-­‐1964   EG-­‐1960   aSAH     aSAH     TBI  $15MM   Phase  3   Phase  3   Phase  2   -­‐   -­‐  $20MM   Phase  3   Phase  3   Phase  3   Phase  2   -­‐  $25MM   Phase  3   Phase  3   Phase  3   Phase  2   Phase  2  26  |  
  27. 27. Corporate  Presenta,on   October  2011  

×